TY - JOUR T1 - SARS-CoV2 disrupts clinical research - the role of a rare disease-specific trial network JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02114-2020 SP - 2002114 AU - Silke van Koningsbruggen-Rietschel AU - Fiona Dunlevy AU - Veerle Bulteel AU - Damian Downey AU - Lieven Dupont Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/07/23/13993003.02114-2020.abstract N2 - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide [1]. This could delay the approval of new medicines and reduce access to investigational treatments via clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. Our survey demonstrates that the European cystic fibrosis clinical trials network is ideally placed to track and address such disruption. ER -